BACKGROUND AND OBJECTIVES: Translocation-associated gene fusions are well recognized in acute myeloid leukemia. Other molecular genetic changes are less well known. The novel cDNA technology has opened the avenue to large-scale gene expression analysis. Our aim was to perform cDNA microarray analysis of acute myeloid leukemia (AML). DESIGN AND METHODS: We performed cDNA microarray analysis using the Clontech hematology filter (containing 406 genes) on 15 patients to study gene expression profiling in AML. As reference, we used whole bone marrow from 5 healthy donors. RESULTS: Our results revealed 50 differentially expressed genes in at least 3 out of 15 patients. Twenty-two genes were upregulated (ratio > or =4), whereas 28 genes were downregulated (ratio < or =0.25). All but one of the 13 genes tested by real-time polymerase chain reaction (PCR) showed the same expression profiles. Among the overexpressed genes, several were those earlier associated with chromosomal translocations and gene fusions. These genes were FGFR1, MYC, NPM1, DEC, and BCL2. The expression of two upregulated genes, HOXA4 and CSF1R, was significantly higher in patients with a white blood cell count higher than 30 x 10(9)/L cells. In patients whose white blood cell count was higher than 100 x 10(9)/L cells, both CLC and GRN were significantly underexpressed, whereas HOXA4 and DAPK1 were overexpressed. FGFR1 and CAMLG were more frequently significantly overexpressed in patients with CD56 immunophenoytpe. INTERPRETATION AND CONCLUSIONS: Clinical and prognostic significance of differential gene expression should be studied with a larger series of patients by using other techniques, such as quantitative real-time PCR.
BACKGROUND AND OBJECTIVES: Translocation-associated gene fusions are well recognized in acute myeloid leukemia. Other molecular genetic changes are less well known. The novel cDNA technology has opened the avenue to large-scale gene expression analysis. Our aim was to perform cDNA microarray analysis of acute myeloid leukemia (AML). DESIGN AND METHODS: We performed cDNA microarray analysis using the Clontech hematology filter (containing 406 genes) on 15 patients to study gene expression profiling in AML. As reference, we used whole bone marrow from 5 healthy donors. RESULTS: Our results revealed 50 differentially expressed genes in at least 3 out of 15 patients. Twenty-two genes were upregulated (ratio > or =4), whereas 28 genes were downregulated (ratio < or =0.25). All but one of the 13 genes tested by real-time polymerase chain reaction (PCR) showed the same expression profiles. Among the overexpressed genes, several were those earlier associated with chromosomal translocations and gene fusions. These genes were FGFR1, MYC, NPM1, DEC, and BCL2. The expression of two upregulated genes, HOXA4 and CSF1R, was significantly higher in patients with a white blood cell count higher than 30 x 10(9)/L cells. In patients whose white blood cell count was higher than 100 x 10(9)/L cells, both CLC and GRN were significantly underexpressed, whereas HOXA4 and DAPK1 were overexpressed. FGFR1 and CAMLG were more frequently significantly overexpressed in patients with CD56 immunophenoytpe. INTERPRETATION AND CONCLUSIONS: Clinical and prognostic significance of differential gene expression should be studied with a larger series of patients by using other techniques, such as quantitative real-time PCR.
Authors: Nirit Mor-Vaknin; Antonello Punturieri; Kajal Sitwala; Neil Faulkner; Maureen Legendre; Michael S Khodadoust; Ferdinand Kappes; Jeffrey H Ruth; Alisa Koch; David Glass; Lilli Petruzzelli; Barbara S Adams; David M Markovitz Journal: Mol Cell Biol Date: 2006-10-09 Impact factor: 4.272
Authors: Ramiro Garzon; Clara D Bloomfield; Dimitrios Papaioannou; Deedra Nicolet; Hatice G Ozer; Krzysztof Mrózek; Stefano Volinia; Paolo Fadda; Andrew J Carroll; Jessica Kohlschmidt; Jonathan E Kolitz; Eunice S Wang; Richard M Stone; John C Byrd Journal: Mol Cancer Ther Date: 2019-06-04 Impact factor: 6.261
Authors: Trisha M Wise-Draper; Hillary V Allen; Elizabeth E Jones; Kristen B Habash; Hiroshi Matsuo; Susanne I Wells Journal: Mol Cell Biol Date: 2006-08-07 Impact factor: 4.272
Authors: Trisha M Wise-Draper; Hillary V Allen; Megan N Thobe; Elizabeth E Jones; Kristen B Habash; Karl Münger; Susanne I Wells Journal: J Virol Date: 2005-11 Impact factor: 5.103
Authors: Pia Riemke; Melinda Czeh; Josephine Fischer; Carolin Walter; Saeed Ghani; Matthias Zepper; Konstantin Agelopoulos; Stephanie Lettermann; Marie L Gebhardt; Nancy Mah; Andre Weilemann; Michael Grau; Verena Gröning; Torsten Haferlach; Dido Lenze; Ruud Delwel; Marco Prinz; Miguel A Andrade-Navarro; Georg Lenz; Martin Dugas; Carsten Müller-Tidow; Frank Rosenbauer Journal: EMBO J Date: 2016-08-29 Impact factor: 11.598
Authors: Tara K Gregory; David Wald; Yichu Chen; Johanna M Vermaat; Yin Xiong; William Tse Journal: J Hematol Oncol Date: 2009-06-02 Impact factor: 17.388